SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Andréia M. Pazini, Guilherme M. Gomes, Jardel G. Villarinho, Claudio Cunha, Francielle Pinheiro, Ana P. O. Ferreira, Carlos F. Mello, Juliano Ferreira, Maribel A. Rubin, Selegiline Reverses Aβ25–35-Induced Cognitive Deficit in Male Mice, Neurochemical Research, 2013, 38, 11, 2287

    CrossRef

  2. 2
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  3. 3
    Thomas Müller, Josef A. Hoffmann, Walter Dimpfel, Christian Oehlwein, Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease, Journal of Neural Transmission, 2013, 120, 5, 761

    CrossRef

  4. 4
    Tamás Tábi, Éva Szökő, László Vécsei, Kálmán Magyar, The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease, Expert Opinion on Drug Metabolism & Toxicology, 2013, 9, 5, 629

    CrossRef

  5. 5
    Alex Rajput, Theresa Zesiewicz, Robert A. Hauser, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  6. 6
    Alex Rajput, Theresa Zesiewicz, Robert Hauser, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  7. 7
    David Salat, Eduardo Tolosa, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  8. 8
    David Salat, Eduardo Tolosa, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  9. 9
    Matthias Löhle, Alexander Storch, Effects of monoamine oxidase Type B inhibitors on motor and non-motor symptoms in Parkinson’s disease: A systematic comparison of rasagiline and selegiline, Basal Ganglia, 2012, 2, 4, S33

    CrossRef

  10. 10
    E. Tolosa, M. B. Stern, Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease, European Journal of Neurology, 2012, 19, 2
  11. 11
    Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong, Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa, Neuropsychopharmacology, 2012, 37, 1, 213

    CrossRef

  12. 12
    Graeme JA Macphee, David A Stewart, Parkinson's disease: treatment and non-motor features, Reviews in Clinical Gerontology, 2012, 22, 04, 243

    CrossRef

  13. You have free access to this content13
    Spyridon (Spyros) Papapetropoulos, Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials, CNS Neuroscience & Therapeutics, 2012, 18, 5
  14. 14
    Joseph Jankovic, Neurology in Clinical Practice, 2012,

    CrossRef

  15. 15
    John Duda, Matthew Stern, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  16. 16
    Rebecca Stowe, Natalie Ives, Carl E. Clarke, Kelly Handley, Alexandra Furmston, Katherine Deane, J.J. van Hilten, Keith Wheatley, Richard Gray, Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease, Movement Disorders, 2011, 26, 4
  17. 17
    William G. Ondo, Motor Complications in Parkinson's Disease, International Journal of Neuroscience, 2011, 121, S2, 37

    CrossRef

  18. 18
    Lawrence Elmer, Robert A Hauser, Strategies for Parkinson’s disease care: prevention and management of motor fluctuations, Neurodegenerative Disease Management, 2011, 1, 5, 415

    CrossRef

  19. 19
    Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz, Cristina Sampaio, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease, Movement Disorders, 2011, 26, S3
  20. 20
    S. Maranis, S. Tsouli, S. Konitsiotis, Treatment of motor symptoms in advanced Parkinson's disease: A practical approach, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 8, 1795

    CrossRef

  21. 21
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  22. 22
    Mercedes Unzeta, Elisenda Sanz, Monoamine Oxidase and their Inhibitors, 2011,

    CrossRef

  23. 23
    Karla Eggert, David Squillacote, Paolo Barone, Richard Dodel, Regina Katzenschlager, Murat Emre, Andrew J. Lees, Olivier Rascol, Werner Poewe, Eduardo Tolosa, Claudia Trenkwalder, Marco Onofrj, Fabrizio Stocchi, Giuseppe Nappi, Vladimir Kostic, Jagoda Potic, Evzen Ruzicka, Wolfgang Oertel, Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study, Movement Disorders, 2010, 25, 7
  24. 24
    Susan Fox, Anthony E. Lang, MOVEMENT DISORDERS 4, 2010,

    CrossRef

  25. 25
    Nancy L Diaz, Cheryl H Waters, Current strategies in the treatment of Parkinson’s disease and a personalized approach to management, Expert Review of Neurotherapeutics, 2009, 9, 12, 1781

    CrossRef

  26. 26
    Mark Stacy, Medical Treatment of Parkinson Disease, Neurologic Clinics, 2009, 27, 3, 605

    CrossRef

  27. 27
    Ripple Talati, Kurt Reinhart, William Baker, C. Michael White, Craig I. Coleman, Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors, Parkinsonism & Related Disorders, 2009, 15, 7, 500

    CrossRef

  28. 28
    Fabrizio Stocchi, The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, S9

    CrossRef

  29. 29
    Ludy Shih, Daniel Tarsy, Pharmacology and Therapeutics, 2009,

    CrossRef

  30. 30
    Marco Onofrj, Laura Bonanni, Astrid Thomas, An expert opinion on safinamide in Parkinson's disease, Expert Opinion on Investigational Drugs, 2008, 17, 7, 1115

    CrossRef

  31. 31
    Joseph Jankovic, Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?, Annals of Neurology, 2008, 63, 3
  32. 32
    Stewart A. Factor, Current status of symptomatic medical therapy in Parkinson’s disease, Neurotherapeutics, 2008, 5, 2, 164

    CrossRef

  33. 33
    Murray Hong, Karim Mukhida, Ivar Mendez, GDNF therapy for Parkinson’s disease, Expert Review of Neurotherapeutics, 2008, 8, 7, 1125

    CrossRef

  34. 34
    Stanley Fahn, How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?, Annals of Neurology, 2008, 64, S2
  35. 35
    Peter A. LeWitt, Levodopa for the Treatment of Parkinson's Disease, New England Journal of Medicine, 2008, 359, 23, 2468

    CrossRef

  36. 36
    Richard B. Dewey, Medical Management of Motor Fluctuations, Neurologic Clinics, 2008, 26, 3, 15

    CrossRef

  37. 37
    Matthias Löhle, Alexander Storch, Orally disintegrating selegiline for the treatment of Parkinson's disease, Expert Opinion on Pharmacotherapy, 2008, 9, 16, 2881

    CrossRef

  38. 38
    Karl Strecker, Johannes Schwarz, Parkinson's disease: emerging pharmacotherapy, Expert Opinion on Emerging Drugs, 2008, 13, 4, 573

    CrossRef

  39. 39
    Kelly E. Lyons, Rajesh Pahwa, Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD - Adjunct Study), Progress in Neurotherapeutics and Neuropsychopharmacology, 2008, 3, 01

    CrossRef

  40. 40
    Lawrence W Elmer, John M Bertoni, The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy, Expert Opinion on Pharmacotherapy, 2008, 9, 16, 2759

    CrossRef

  41. 41
    Fabrizio Stocchi, Michele Tagliati, C. Warren Olanow, Treatment of levodopa-induced motor complications, Movement Disorders, 2008, 23, S3
  42. 42
    Peter A. LeWitt, A Perspective on Adjunctive Therapy for Parkinson Disease With Monoamine Oxidase-B Inhibition, Clinical Neuropharmacology, 2007, 30, 5, 305

    CrossRef

  43. 43
    Robert A. Hauser, Theresa A. Zesiewicz, Advances in the Pharmacologic Management of Early Parkinson Disease, The Neurologist, 2007, 13, 3, 126

    CrossRef

  44. 44
    Jack J Chen, Hubert H Fernandez, Community and Long-Term Care Management of Parkinson???s Disease in the Elderly, Drugs & Aging, 2007, 24, 8, 663

    CrossRef

  45. 45
    Werner H Poewe, Olivier Rascol, Niall Quinn, Eduardo Tolosa, Wolfgang H Oertel, Emilia Martignoni, Markus Rupp, Babak Boroojerdi, Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial, The Lancet Neurology, 2007, 6, 6, 513

    CrossRef

  46. 46
    Neal Hermanowicz, Letter to the editors, The American Journal of Geriatric Pharmacotherapy, 2007, 5, 2, 174

    CrossRef

  47. 47
    Joseph Jankovic, Mark Stacy, Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease, CNS Drugs, 2007, 21, 8, 677

    CrossRef

  48. 48
    Hubert H. Fernandez, Jack J. Chen, Monamine Oxidase Inhibitors, Clinical Neuropharmacology, 2007, 30, 3, 150

    CrossRef

  49. 49
    Hubert H. Fernandez, Jack J. Chen, Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007, 27, 12P2
  50. 50
    William G. Ondo, Placebo Response in Parkinson Trials Using Patient Diaries, Clinical Neuropharmacology, 2007, 30, 5, 301

    CrossRef

  51. 51
    Mark F. Lew, Rajesh Pahwa, Maureen Leehey, John Bertoni, Greg Kricorian, Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of ‘off’ episodes in patients with Parkinson's disease, Current Medical Research and Opinion, 2007, 23, 4, 741

    CrossRef

  52. 52
    William G. Ondo, Kapil D. Sethi, Greg Kricorian, Selegiline Orally Disintegrating Tablets in Patients With Parkinson Disease and "Wearing Off" Symptoms, Clinical Neuropharmacology, 2007, 30, 5, 295

    CrossRef

  53. 53
    Amos D Korczyn, Transdermal therapy in Parkinson's disease, The Lancet Neurology, 2007, 6, 6, 475

    CrossRef

  54. 54
    Kathleen L Poston, Cheryl Waters, Zydis selegiline in the management of Parkinson's disease, Expert Opinion on Pharmacotherapy, 2007, 8, 15, 2615

    CrossRef

  55. 55
    Anthony Clarke, Joseph Jankovic, Selegiline orally disintegrating tablet in the treatment of Parkinsons disease, Therapy, 2006, 3, 3, 349

    CrossRef

  56. 56
    John C Morgan, Kapil D Sethi, Emerging drugs for Parkinson’s disease, Expert Opinion on Emerging Drugs, 2006, 11, 3, 403

    CrossRef

  57. 57
    Aloke K Dutta PhD, Weidong Le MD, PhD, Existing dopaminergic therapies for Parkinson’s disease, Expert Opinion on Therapeutic Patents, 2006, 16, 12, 1613

    CrossRef

  58. 58
    Daniel Tarsy, Initial treatment of parkinson’s disease, Current Treatment Options in Neurology, 2006, 8, 3, 224

    CrossRef

  59. 59
    John T Slevin, Melody Ryan, Orally disintegrating carbidopa/levodopa, Future Neurology, 2006, 1, 2, 139

    CrossRef

  60. 60
    F. Stocchi, Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease, International Journal of Clinical Practice, 2006, 60, 2
  61. 61
    M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease, European Journal of Neurology, 2006, 13, 11
  62. 62
    John C Morgan, Kapil D Sethi, Rotigotine for the treatment of Parkinson’s disease, Expert Review of Neurotherapeutics, 2006, 6, 9, 1275

    CrossRef

  63. 63
    Anthony Clarke, Joseph Jankovic, Selegiline orally disintegrating tablet in the treatment of Parkinson’s disease, Therapy, 2006, 3, 3, 349

    CrossRef

  64. 64
    Alan Diamond, Joseph Jankovic, Treatment of advanced Parkinson’s disease, Expert Review of Neurotherapeutics, 2006, 6, 8, 1181

    CrossRef

  65. 65
    Tom H Johnston, Susan H Fox, Jonathan M Brotchie, Advances in the delivery of treatments for Parkinson’s disease, Expert Opinion on Drug Delivery, 2005, 2, 6, 1059

    CrossRef

  66. 66
    Andrew Lees, Alternatives to Levodopa in the Initial??Treatment of Early Parkinson???s Disease, Drugs & Aging, 2005, 22, 9, 731

    CrossRef

  67. 67
    H. Reichmann, Medikamentöse Parkinson-Therapie, Der Nervenarzt, 2005, 76, 12, 1547

    CrossRef

  68. 68
    Cheryl Waters, Other pharmacological treatments for motor complications and dyskinesias, Movement Disorders, 2005, 20, S11
  69. 69
    Claire Henchcliffe, H Christian Schumacher, F Tuna Burgut, Recent advances in Parkinson’s disease therapy: use of monoamine oxidase inhibitors, Expert Review of Neurotherapeutics, 2005, 5, 6, 811

    CrossRef

  70. 70
    Mark F Lew, Selegiline orally disintegrating tablets for the treatment of Parkinson’s disease, Expert Review of Neurotherapeutics, 2005, 5, 6, 705

    CrossRef

  71. 71
    Isabel Gomez-Orellana, Strategies to improve oral drug bioavailability, Expert Opinion on Drug Delivery, 2005, 2, 3, 419

    CrossRef

  72. 72
    &NA;, SYMPOSIUM REPORTER 2005, Journal of the American Medical Directors Association, 2005, 6, Supplement 2, iii,4???16

    CrossRef

  73. 73
    Stéphane Thobois, Florence Delamarre-Damier, Pascal Derkinderen, Treatment of motor dysfunction in Parkinson's disease: an overview, Clinical Neurology and Neurosurgery, 2005, 107, 4, 269

    CrossRef

  74. 74
    Richard Robinson, NEW INTEREST IN MAO INHIBITORS FOR PARKINSON DISEASE, Neurology Today, 2004, 4, 10, 46,47,48

    CrossRef

  75. 75
    David B. Sommer, Larry B. Goldstein, Central Nervous System (CNS), Wiley Encyclopedia of Clinical Trials,
  76. 76
    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley, Alex Furmston, Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications, The Cochrane Library,
  77. 77
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Late (Complicated) Parkinson's Disease,
  78. 78
    Miguel Coelho, Joaquim Ferreira, Cristina Sampaio, Parkinson's Disease,
  79. 79
    Dulce Neutel, Joaquim Ferreira, Miguel M Coelho, João Costa, Mário Miguel Rosa, Olivier Rascol, Cristina Sampaio, Rasagiline for levodopa-induced motor complications in Parkinson´s disease, The Cochrane Library,